浆液性交界性卵巢肿瘤与低级别浆液性卵巢癌
本文阐述低级别浆液性卵巢癌(LGSOC)的病理、分子生物学和治疗选择,并在一组33例经病理证实的LGSOC患者中展示原发肿瘤及转移灶的影像表现,同时阐明LGSOC与高级别浆液性卵巢癌(HGSOC)的差异,并描述浆液性交界性卵巢肿瘤(SBOT)的影像表现及与LGSOC的鉴别要点。
要点
- LGSOC仅占卵巢癌的2-5%,其影像表现数据有限,需与HGSOC区分。
- LGSOC常起源于浆液性交界性卵巢肿瘤(SBOT),两者影像表现需鉴别。
- 本文展示33例病理证实的LGSOC原发灶及转移灶影像表现。
核心结论
- LGSOC与HGSOC在分子生物学和临床病程上是完全不同的实体,LGSOC常起源于SBOT,本文展示了LGSOC原发及转移灶的影像表现并阐明其与HGSOC及SBOT的差异。
研究设计与样本
- 本文为影像学论述,纳入33例经病理证实的LGSOC患者,展示其原发肿瘤及转移灶的影像表现,并阐述病理、分子生物学和治疗选择。
局限性
- 由于LGSOC患病率低,其影像表现数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Epithelial ovarian cancer (EOC) is the most frequent histological subtype of ovarian cancer, accounting for 95% of ovarian cancer. Radiologists are familiar with the imaging appearances of high-grade serous ovarian cancer (HGSOC) that accounts for about 70% of EOC. Low grade serous ovarian cancer (LGSOC) represents 2-5% of ovarian carcinomas and 5-10% of serous ovarian carcinoma. Historically, it was thought that LGSOC and HGSOC were a continuum. It is now clear that these are two completely separate entities. They have different molecular biology and clinical course. As a result of the low prevalence of LGSOC, there is limited data on its imaging findings. In this paper, we illustrate the pathology, molecular biology and treatment options of LGSOC. We present imaging appearances of LGSOC of primary tumor and metastasis in a cohort of 33 patients with pathologically-proven LGSOC. We also elucidate the differences between LGSOC and HGSOC. Since LGSOC often arise from serous borderline ovarian tumors (SBOT), we describe the imaging appearances of SBOT and highlight the differences between these two entities.
引用
- Sandrasegaran K, Das A, Shah A, et al. Serous borderline ovarian tumor and low-grade serous ovarian cancer. Abdom Radiol (NY). 2025. PMID: 40748460. doi:10.1007/s00261-025-05143-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。